🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06596785
Active, not recruiting Observational

Risk Factors and Deep Learning Model for CI-AKI

NCT06596785 · tracked via the Priya Life Science China tracker
Sponsor
Xiao Li,MD
Phase
Observational
Started
2024-06-01
Last updated
2024-09-19

Condition(s) studied

AKI - Acute Kidney Injury

Study summary

Contrast-associated acute kidney injury (CI-AKI) is a sudden and significant decline in renal function resulting from the use of a contrast agent.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: * patients who received iodinated contrast agents during hospitalization * age ≥ 18 years * hospitalization length ≥ 48 hours * at least two serum creatinine tests during hospitalization Exclusion Criteria: * patients with stage 4 or 5 chronic kidney disease prior to admission * patients undergoing hemodialysis, hemofiltration or peritoneal before admission * a history of nephrectomy or kidney transplantation during hospitalization * incomplete clinical information * Serum creatinine always ≤ 40 μmol/L during hospitalization

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan Shandong

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06596785 on ClinicalTrials.gov ↗ ← All trials in China